7th Global Biopharma CEO / top execs virtual press briefing – COVID-19
For any questions, please contact:
COVID-19 vaccines and treatments – industry update on progress and outlook
Organized by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) – representing the global innovative biopharmaceutical industry committed to addressing the novel cvoronavirus public health crisis.
Bill Anderson is the CEO of Roche Pharmaceuticals. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.
Bill serves as a member of Roche’s Executive Committee, overseeing the Pharmaceutical division. Leading an organisation of 55,000 people, he is passionate about helping people make meaningful progress every day on the things that matter to patients. With a world-leading investment in R&D, his vision is to bring more medical advances to patients at less cost to society.
His tenure at Roche has seen him serve as the CEO of Genentech, the Head of Global Product Strategy and in roles leading the US Oncology and Immunology business units. Bill has a bachelor’s degree in chemical engineering from the University of Texas and earned masters degrees in management and chemical engineering from the Massachusetts Institute of Technology.
Albert Bourla leads Pfizer in its purpose, Breakthroughs that change patients’ lives, with a focus on driving the scientific and commercial innovation needed to have a transformational impact on human health. When he became CEO in 2019, Albert accelerated Pfizer’s transformation to become a more science-driven, innovative company and fostered a culture in which people and science could thrive.
During his more than 25 years at Pfizer, Albert has built a diverse and successful career, holding senior positions across a range of markets and disciplines, which has informed his understanding of the needs of patients and deepened his commitment to helping ensure equitable access to medicines and vaccines.
Albert is a Doctor of Veterinary Medicine and holds a Ph.D. from the Veterinary School of Aristotle University. In 2022, he was named the Genesis Prize Laureate in recognition of his leadership during the pandemic. In 2021, he was named CEO of the Year by CNN Business, included in Insider Magazine’s Most Transformative CEOs list and inducted into the Crain’s New York Business Hall of Fame. Albert is on the executive committee of The Partnership for New York City, a vice president of the International Federation of Pharmaceutical Manufacturers & Associations, a director on multiple boards and a Trustee of the United States Council for International Business.
He is also a member of the Council on Foreign Relations, the Business Roundtable, the Business Council and the New York City Mayor’s Corporate Council.
Dave Ricks is chair and chief executive officer of Eli Lilly and Company. A Lilly veteran for more than 25 years, with experience in marketing, sales, drug development and international operations, Dave became CEO in January 2017 and was elected chair of the company’s board of directors effective June 2017.
Dave served as president of Lilly Bio-Medicines from 2012 through 2016. He led the company’s largest affiliate, Lilly USA, as president from 2009 to 2012.
Prior to that, Dave served in international leadership roles for nearly eight years. He served as president and general manager of Lilly China, operating in one of the world’s fastest-growing emerging markets, from 2008 to 2009. He led Lilly Canada as general manager from 2005 to 2008, after roles as director of pharmaceutical marketing and national sales director in that country. Dave joined Lilly in 1996 as a business development associate and held several management roles in U.S. marketing and sales before moving to Lilly Canada.
Dave earned a Bachelor of Science degree from Purdue University in 1990 and a Master of Business Administration degree from Indiana University in 1996.
Dave is on the board of Adobe and is the immediate past chair of the board of the Pharmaceutical Research and Manufacturers of America (PhRMA). Dave is a member of the International Federation of Pharmaceutical Manufacturers & Association’s CEO Steering Committee, The Business Council, Business Roundtable, and the U.S. Patent and Trademark Office’s Council for Inclusive Innovation.
Closer to home, Dave is also heavily engaged in the development and well-being of Central Indiana. He serves on the board of the Central Indiana Corporate Partnership and on the Riley Children’s Foundation board of governors.
As Director General, Thomas leads IFPMA’s mission to encourage the development of sustainable solutions that enable innovation and improve global health.
Over the past two decades, Thomas has been instrumental in developing collaborative solutions for some of the greatest global health challenges. These include HIV/AIDS and antimicrobial resistance, as well as the industry’s response to pandemics.
He is frequently called upon to comment on industry’s contribution to global health in the world media and at international fora.
Since he joined IFPMA, Thomas has pioneered collaborative solutions to tackle antimicrobial resistance (AMR), chairing the AMR Industry Alliance and launching the AMR Action Fund. This is a USD 1 billion venture begun in July 2020 to fund the development of between two and four new antibiotics by 2030.
Thomas represents the innovative pharmaceutical industry in the Access to COVID-19 Tools (ACT) Accelerator initiative, set up in April 2019. In 2022, together with industry CEOs and building on the lessons learned from COVID-19, he led the development of the Berlin Declaration. This is a vision for equitable access in global pandemic response that invites multilateral organizations as well as the G7 and G20 to agree to a social contract for future health security.
He is Chair of the Business at OECD Health Committee and serves as Industry Co-Chair of the APEC Biopharmaceutical Working Group on Ethics.
COVID-19 vaccines and treatments output continues apace; as health systems and last mile hurdles remain collective stumbling blocks
To date, over 13 billion doses of COVID-19 vaccines have been produced and 11 billion have been administered. Presently, vaccine supplies outstrip global demand, with voluntary technology transfer playing a significant role. Urgent steps are needed to provide a high level of protection against COVID-19 among the elderly and vulnerable populations wherever they live. Several...Read more
Introductory remarks by Thomas Cueni at IFPMA media briefing on 13 April 2022
Thank you again for joining us for this media briefing that will give you a snapshot of what biopharmaceutical companies continue to innovate and manufacture in response to the pandemic. Already last year, we were telling policy makers that supplies of COVID-19 vaccines were fast out-stripping demand. We ended 2021 with over 11 billion vaccines...Read more